Eli Lilly and Company (FRA:LLY)
Germany · Delayed Price · Currency is EUR | Market Cap | 580.81B |
| Revenue (ttm) | 45.34B |
| Net Income (ttm) | 10.28B |
| Shares Out | n/a |
| EPS (ttm) | 11.37 |
| PE Ratio | 56.52 |
| Forward PE | 29.06 |
| Dividend | 5.18 (0.78%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 831 |
| Average Volume | 359 |
| Open | 665.90 |
| Previous Close | 668.30 |
| Day's Range | 629.80 - 668.00 |
| 52-Week Range | 616.90 - 888.80 |
| Beta | n/a |
| RSI | 47.86 |
| Earnings Date | Aug 7, 2025 |
About MorphoSys AG
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsNews
Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health
Eli Lilly and Co. LLY released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity...
Elli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the older drug Trulicity.
Eli Lilly's Mounjaro met goal of cardiovascular benefit in head-to-head trial with Trulicity
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news from Eli Lilly.
Mounjaro proves more heart protective than Trulicity in trial of Eli Lilly diabetes drugs
Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling medication for the disease, in reducing the risk of heart attack and stroke in a lar...
Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
Eli Lilly said its blockbuster diabetes drug Mounjaro showed similar heart health benefits as the company's older diabetes treatment, Trulicity, in a late-stage trial directly comparing the two medici...
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated ...
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the valu...
Why Eli Lilly Stock Was Looking Sickly Today
It seemed the market overreacted to discouraging news from one of the company's rivals.
Lilly set for strong quarter after Novo profit warning
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook a...
Trump's pharmaceutical tariffs could affect some drugmakers more than others
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
What's Going On With Eli Lilly Stock On Tuesday?
Eli Lilly and Co. (NYSE: LLY) stock is trading lower on Tuesday after its weight loss drug rival, Novo Nordisk A/S (NYSE: NVO), trimmed its 2025 financial outlook. The cut marks the second time this...
What other health conditions are weight-loss drugs being tested for?
Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival medicines Ozempic and Wegovy are being studied to see whether they can improve health i...
Ozempic makers shares plunge $70bn as copycats bite into weight loss market
Investors knocked $70bn off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the obesi...
LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases
REDWOOD CITY, Calif. & SHENZHEN, China--(BUSINESS WIRE)--LTZ's research collaboration with Lilly advances development of its novel Myeloid Engager Platform, addressing diseases with high unmet need.
Wegovy maker Novo Nordisk’s shares plunge as it cuts sales forecast
Pharma group names Maziar Mike Doustdar as new CEO as it seeks to convince investors it is not lagging behind rival Eli Lily Business live – latest updates The obesity drugmaker Novo Nordisk has cut i...
Eli Lilly’s Jaypirca succeeds in late-stage trial against Imbruvica of J&J and AbbVie
Lilly's cancer drug more effective than AbbVie's in head-to-head study
Eli Lilly said on Tuesday its drug, Jaypirca, was more effective in a head-to-head study against AbbVie's Imbruvica when tested in patients with a type of blood cancer.
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL
Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05 Progression-free survival data was immature, but trending ...
AI Is Driving Healthtech Investments To New Heights, But Watch These 3 Overlooked Areas
Investments in AI have been gaining rapid momentum across industries, however 2025 is proving to be the year that it's taking off in the healthcare space. This has been accelerated by several huge fun...
Thousands of Americans are being forced to switch from Zepbound to Wegovy as a result of new coverage restrictions by CVS Caremark. ‘I just wish they would trust my doctor.
Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.
Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China
In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like...
3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs
On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in ...
The Big 3: OKTA, LLY, ADSK
@ProsperTradingAcademy's Charles Moon turns to three names he sees making notable recoveries in their stock price. He talks about the "great upside" Okta Inc. (OKTA) holds, Eli Lilly's (LLY) "technica...
EU medicines agency reverses course on Eli Lilly’s Alzheimer drug
The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects
Eli Lilly's Options Frenzy: What You Need to Know
Deep-pocketed investors have adopted a bullish approach towards Eli Lilly (NYSE: LLY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...